19 December 2022 in Clinical Cancer Research
Purpose: The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved for patients with metastatic urothelial carcinoma (mUC) without prior assessment of the tumor receptor status as ubiquitous NECTIN-4 expression is assumed. Our objective was to determine the prevalence of membranous NECTIN-4 protein expression in primary tumors (PRIM) and patient-matched distant metastases (MET). Experimental Design: Membranous NECTIN-4 protein expression was measured (H-score) by IHC in PRIM and corresponding MET (N = 137) and in a multicenter EV-treated cohort (N = 47). Progression-free survival (PFS) after initiation of EV treatment was assessed for the NECTIN-4–negative/weak (H-score 0–99) versus moderate/strong (H-score 100–300) subgroup. The specificity of the NECTIN-4 IHC staining protocol was validated by establishing CRISPR-Cas9–induced polyclonal NECTIN-4 knockouts. Results: In our cohort, membranous NECTIN-4 expression significantly decreased during metastatic spread (Wilcoxon matched pairs P < 0.001; median H-score = 40; interquartile range, 0–140), with 39.4% of MET lacking membranous NECTIN-4 expression. In our multicenter EV cohort, absence or weak membranous NECTIN-4 expression (34.0% of the cohort) was associated with a significantly shortened PFS on EV (log-rank P < 0.001). Conclusions: Membranous NECTIN-4 expression is frequently decreased or absent in mUC tissue. Of note, the clinical benefit of EV strongly depends on membranous NECTIN-4 expression. Thus, our results are of highest clinical relevance and argue for a critical reconsideration of the current practice and suggest that the NECTIN-4 receptor status should be determined (ideally in a metastatic/progressive lesion) before initiation of EV. See related commentary by Aggen et al., p. 1377
28 September 2026 in Clinical Cancer Research
Purpose: Enfortumab vedotin (EV) is standard therapy for metastatic urothelial carcinoma (mUC), yet the predictive relevance of Nectin cell adhesion molecule 4 (NECTIN4) expression—especially membranous versus cytoplasmic—remains unclear. In this study, we sought to extend previous findings on NECTIN4 gene amplification in parallel with a systematic subcellular evaluation of Nectin-4 expression. Experimental Design: We retrospectively analyzed 179 EV-treated patients with mUC. NECTIN4 amplification was assessed by fluorescence in situ hybridization (FISH) and Nectin-4 protein levels by immunohistochemistry (IHC). A four-tier membranous scoring algorithm (0, 1+, 2+, and 3+) adapted from the College of American Pathologists (CAP) HER2 gastric guidelines was benchmarked against H-score. We integrated amplification status with membranous staining to refine predictive stratification and compared associations with objective response rate (ORR) with those observed in EV-301 data. Results: Combining membranous and cytoplasmic compartments resulted in a median composite H-score of 260 (78.2% ≥ 150), closely matching Nectin-4 expression prevalence reported in EV-301 (median, 250; 82.6% ≥ 150). A ≥150 cutoff enriched for EV responders in both cohorts, with an ORR of 45.8% versus 20% (P = 0.001) in EV-301. High membranous expression based on the scoring (2+/3+) predicted response (ORR, 55.1% vs. 25.5%; P < 0.001), with longer progression-free survival [PFS; 7.1 vs. 2.9 months; hazard ratio (HR) = 0.45] and overall survival (OS; 12.3 vs. 6.9 months; HR = 0.57), whereas cytoplasmic expression lacked predictive value. NECTIN4-amplified tumors showed particularly favorable outcomes (PFS, 12.2 months; OS, 30.1 months). An integrated three-tier model—amplified, nonamplified/high-membranous, and nonamplified/low-membranous—yielded ORRs of 77.2%, 42.9%, and 26.1% and separated survival outcomes. Conclusions: Our Nectin-4 scoring system integrating NECTIN4 amplification with membranous Nectin-4 expression accurately predicts outcomes, supporting combined genomic and membranous assessment as complementary biomarkers for optimizing EV selection. See related article by YYY, p. XX .
11 August 2026 in Urologic Oncology: Seminars and Original Investigations
MQMaria Natalia Gandur Quiroga
Maria Natalia Gandur Quiroga
Recent advances in metastatic prostate cancer (mCaP) have increasingly focused on molecularly targeted therapies, particularly those addressing alterations in DNA damage repair (DDR) pathways. Poly(ADP-ribose) polymerase inhibitors (PARPis) have demonstrated substantial and clinically meaningful efficacy in patients harboring homologous recombination repair (HRR) gene alterations, most notably BRCA1/2, as well as selected additional DDR genes. To expand the population that may benefit from PARPi therapy, multiple combination strategies are currently being explored. This narrative review provides an overview of the current evidence on the role of PARPi in mCaP, summarizes their clinical implementation, and discusses future perspectives, including rational combination approaches and potential applications in earlier disease stages. PARPi demonstrate the most pronounced and consistent efficacy in BRCA-mutated CaP. Patients with non-BRCA HRR alterations may derive heterogeneous but potentially meaningful benefit from PARPi, particularly when PARPi are combined with androgen-receptor pathway inhibitors (ARPI). While activity of PARPi monotherapy is limited in patients without detectable HRR alterations, emerging data indicate clinically relevant benefit in selected subgroups treated with PARPi-based combinations, potentially mediated by functional DNA repair deficiencies, androgen-receptor (AR)-PARP pathway crosstalk, or treatment-induced "BRCAness." Refinement of biomarker strategies and improved molecular stratification are, therefore, critical to extend PARPi benefit beyond classical HRR alterations. Nevertheless, a standardized framework defining the optimal timing of HRR testing and the clinical relevance of individual gene alterations remains to be established. PARPi are now firmly established as an important targeted treatment option in metastatic castration-resistant CaP (mCRCaP), with therapeutic efficacy closely linked to tumor genomic features. However, the identification of robust predictive biomarkers beyond BRCA1/2 and the optimal integration of combination therapies remain key challenges. Emerging evidence supports further evaluation of PARPi-based combinations, as well as their earlier use in disease stages such as metastatic hormone-sensitive CaP (mHSCaP), which may ultimately broaden their clinical impact.